Long non‑coding RNA DSCAM‑AS1 functions as an oncogene in thyroid cancer via regulating miR‑211

Hua,Tebo; Yang,Jiahui; Zhu,Ye; Luo,Yong

doi:10.3892/ol.2023.13752

Long non‑coding RNA DSCAM‑AS1 functions as an oncogene in thyroid cancer via regulating miR‑211

Authors:
- Tebo Hua
- Jiahui Yang
- Ye Zhu
- Yong Luo
View Affiliations

Affiliations: Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Department of Thyroid Breast Surgery, Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China
Published online on: March 8, 2023 https://doi.org/10.3892/ol.2023.13752
Article Number: 165
Copyright: © Hua et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA Down syndrome cell adhesion molecule‑antisense 1 (DSCAM‑AS1) has been reported to play key roles in the progression and initiation of several cancer types. However, the various functional roles of DSCAM‑AS1 in thyroid cancer tumorigenesis remain largely elusive. In the present study, the expression of DSCAM‑AS1 was examined in thyroid cancer tissues and cell lines. Cell Counting Kit‑8, wound healing, Transwell and clonogenic assays were conducted to detect cell proliferation, migration, invasion and colony formation, respectively. The association of DSCAM‑AS1 with microRNA 211 (miR‑211) was determined by luciferase reporter assay. It was found that the expression of DSCAM‑AS1 was upregulated in thyroid cancer cells and tissues. Furthermore, enhanced DSCAM‑AS1 expression was positively associated with lymph node metastasis and tumor‑node‑metastasis stage. Functional experiments demonstrated that DSCAM‑AS1 knockdown inhibited the migration, proliferation and invasion of TPC‑1 cells. Mechanistically, DSCAM‑AS1 could bind to miR‑211. Prevention of miR‑211 by a miR‑211 inhibitor reversed the effect of DSCAM‑AS1 depletion in thyroid cancer tumorigenesis. Briefly, the current findings suggested that knockdown of DSCAM‑AS1 suppressed the tumorigenesis of thyroid cancer via regulating miR‑211, suggesting that DSCAM‑AS1 may be a favorable therapeutic target for thyroid cancer.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Pratilas CA and Solit DB: Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials. 2:121–134. 2007. View Article : Google Scholar : PubMed/NCBI
3	Suzuki K, Iwai H, Utsunomiya K, Kono Y, Watabe T, Kobayashi Y, Bui DV, Sawada S, Yun Y, Mitani A, et al: Efficacy of combination therapy with lenvatinib and radioactive iodine in thyroid cancer preclinical model. Int J Mol Sci. 23:98722022. View Article : Google Scholar : PubMed/NCBI
4	Li M, Dal Maso L and Vaccarella S: Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8:468–470. 2020. View Article : Google Scholar : PubMed/NCBI
5	Guttman M, Russell P, Ingolia NT, Weissman JS and Lander ES: Ribosome profiling provides evidence that large noncoding RNAs do not encode proteins. Cell. 154:240–251. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sun T: Long noncoding RNAs act as regulators of autophagy in cancer. Pharmacol Res. 129:151–155. 2018. View Article : Google Scholar : PubMed/NCBI
8	Sedaghati M and Kebebew E: Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 26:275–281. 2019. View Article : Google Scholar : PubMed/NCBI
9	Javed Z, Ahmed Shah F, Rajabi S, Raza Q, Iqbal Z, Ullah M, Ahmad T, Salehi B, Sharifi-Rad M, Pezzani R, et al: LncRNAs as potential therapeutic targets in thyroid cancer. Asian Pac J Cancer Prev. 21:281–287. 2020. View Article : Google Scholar : PubMed/NCBI
10	Cao J, Zhang M, Zhang L, Lou J, Zhou F and Fang M: Non-coding RNA in thyroid cancer-Functions and mechanisms. Cancer Lett. 496:117–126. 2021. View Article : Google Scholar : PubMed/NCBI
11	Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al: The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 7:127912016. View Article : Google Scholar : PubMed/NCBI
12	Winkle M, El-Daly SM, Fabbri M and Calin GA: Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
13	Hill M and Tran N: miRNA interplay: Mechanisms and consequences in cancer. Dis Model Mech. 14:dmm0476622021. View Article : Google Scholar : PubMed/NCBI
14	Li B, Cao Y, Sun M and Feng H: Expression, regulation, and function of exosome-derived miRNAs in cancer progression and therapy. FASEB J. 35:e219162021. View Article : Google Scholar : PubMed/NCBI
15	Ghafouri-Fard S, Shirvani-Farsani Z and Taheri M: The role of microRNAs in the pathogenesis of thyroid cancer. Noncoding RNA Res. 5:88–98. 2020. View Article : Google Scholar : PubMed/NCBI
16	Geropoulos G, Psarras K, Papaioannou M, Giannis D, Meitanidou M, Kapriniotis K, Symeonidis N, Pavlidis ET, Pavlidis TE, Sapalidis K, et al: Circulating microRNAs and clinicopathological findings of papillary thyroid cancer: A systematic review. In vivo. 36:1551–1569. 2022. View Article : Google Scholar : PubMed/NCBI
17	Ji D, Hu G, Zhang X, Yu T and Yang J: Long non-coding RNA DSCAM-AS1 accelerates the progression of hepatocellular carcinoma via sponging miR-338-3p. Am J Transl Res. 11:4290–4302. 2019.PubMed/NCBI
18	Li Y, Hao J, Jiang YM, Liu Y and Zhang SH: Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4. Eur Rev Med Pharmacol Sci. 24:109152020.PubMed/NCBI
19	Hua T and Luo Y: Circular RNA PVT1 promotes progression of thyroid cancer by competitively binding miR-384. Exp Ther Med. 24:6292022. View Article : Google Scholar : PubMed/NCBI
20	Huang X, Wang Z, Hou S, Yue C, Li Z, Hu W and Lu H: Long non-coding RNA DSCAM-AS1 promotes pancreatic cancer progression via regulating the miR-136-5p/PBX3 axis. Bioengineered. 13:4153–4165. 2022. View Article : Google Scholar : PubMed/NCBI
21	Liang J, Zhang S, Wang W, Xu Y, Kawuli A, Lu J and Xiu X: Long non-coding RNA DSCAM-AS1 contributes to the tumorigenesis of cervical cancer by targeting miR-877-5p/ATXN7L3 axis. Biosci Reps. 40:BSR201920612020. View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang C, Yan G, Zhang Y, Jia X and Bu P: Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1. Neoplasma. 62:541–549. 2015. View Article : Google Scholar : PubMed/NCBI
24	Liu H, Deng H, Zhao Y, Li C and Liang Y: LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 37:2792018. View Article : Google Scholar : PubMed/NCBI
25	Guo K, Qian K, Shi Y, Sun T and Wang Z: LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis. 12:10972021. View Article : Google Scholar : PubMed/NCBI
26	Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
27	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ma Y, Bu D, Long J, Chai W and Dong J: LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. J Cell Physiol. 234:2880–2894. 2019. View Article : Google Scholar : PubMed/NCBI
29	Liang WH, Li N, Yuan ZQ, Qian XL and Wang ZH: DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Mol Carcinog. 58:461–473. 2019. View Article : Google Scholar : PubMed/NCBI
30	Wang L, Shen YF, Shi ZM, Shang XJ, Jin DL and Xi F: Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11. J Clin Lab Anal. 32:e222932018. View Article : Google Scholar : PubMed/NCBI
31	Liang M, Jia J, Chen L, Wei B, Guan Q, Ding Z, Yu J, Pang R and He G: LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer. Endocrine. 65:318–326. 2019. View Article : Google Scholar : PubMed/NCBI